Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
First-in-human clinical trial investigating Enveric's lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or…
Read More
Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated…
Read More
30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
